<DOC>
	<DOCNO>NCT00458016</DOCNO>
	<brief_summary>The purpose study collect important information regard safety , tolerability , efficacy MB07803 administer 28 day patient type 2 diabetes mellitus</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Study MB07803 Administered Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Fasting plasma glucose 120 270 mg/dL screen HbA1c measurement 6.0 10 % screening Females surgically sterile ( i.e . woman hysterectomy tubal ligation ) . Females postmenopausal least 12 consecutive month document blood follicular stimulate hormone ( FSH ) great equal 40 mlU/mL.Females childbearing potential must willing use approve doublebarrier method birth control ( e.g . condom plus spermicide ; IUD plus spermicide ) time sign informed consent form 4 week follow last dose study drug . Body mass index ( BMI ) range 18.5 37 kg/m2 Patients BMI range 37.5 40 kg/m2 Investigator 's opinion , good health satisfy eligibility criterion , consider caseby case basis Written inform consent Type 1 diabetes mellitus Type 2 diabetes mellitus history diabetic ketoacidosis ketosisprone Use thiazolidinediones ( TZDs ) Currently two oral hypoglycemic agent History outpatient insulin use Clinically significant history cardiac disease within 6 month inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>